Rocket Pharmaceuticals grants equity to COO Stevens
Rocket Pharmaceuticals’ Chief Operating Officer Christopher James Stevens received equity compensation on August 3, 2026, consisting of 101,428 stock options at an exercise price of $3.41 expiring August 3, 2036, and 73,313 RSUs.
Rhea-AI Filing Summary
Rocket Pharmaceuticals’ Chief Operating Officer Christopher James Stevens received equity compensation on August 3, 2026, consisting of 101,428 stock options at an exercise price of $3.41 expiring August 3, 2036, and 73,313 RSUs. Both awards vest one-third on August 3, 2027, with the remaining portions vesting in equal quarterly installments over the following two years. After these grants, he directly holds 542,442 shares of common stock, including RSUs, plus the option to purchase 101,428 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 174,741 shares
Grant/Award
2 txns
Insider
Stevens Christopher James
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F3 | 101,428 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1, F2 | 73,313 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 101,428 contracts (Direct);
Common Stock — 542,442 shares (Direct)
Footnotes (3)
- F1. Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
- F2. Represents RSUs, one-third (1/3) of which will become fully vested on August 3, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
- F3. This option represents a right to purchase a total of 101,428 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on August 3, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
Key Figures
Stock options granted: 101,428 shares
Option exercise price: $3.41 per share
Option expiration date: August 3, 2036
+3 more
6 metrics
Stock options granted
101,428 shares
Stock Option (Right to Buy) granted to COO on August 3, 2026
Option exercise price
$3.41 per share
Conversion or exercise price for the stock option grant
Option expiration date
August 3, 2036
Expiration date of the 101,428-share stock option grant
RSUs granted
73,313 shares
Restricted Stock Units granted August 3, 2026 that convert one-for-one to common stock
Common stock holdings after grant
542,442 shares
Total direct common stock holdings, including RSUs, following the RSU grant
Initial vesting date
August 3, 2027
One-third of both the RSUs and stock options become fully vested on this date
Key Terms
Restricted Stock Units ("RSUs"), one-for-one basis, vesting in equal quarterly installments, right to purchase
4 terms
Restricted Stock Units ("RSUs") financial
"Holdings include Restricted Stock Units ("RSUs") that convert to common stock"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
one-for-one basis financial
"RSUs that convert to common stock on a one-for-one basis"
vesting in equal quarterly installments financial
"remaining shares vesting in equal quarterly installments over the following two years"
right to purchase financial
"This option represents a right to purchase a total of 101,428 shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did RCKT grant to COO Christopher James Stevens?
Christopher James Stevens received 101,428 stock options with a $3.41 exercise price and 73,313 RSUs. Both awards were granted on August 3, 2026 and vest one-third on August 3, 2027, then in equal quarterly installments over the following two years.
What is the exercise price and expiration date of Stevens’ new RCKT options?
The stock option grant covers 101,428 shares at an exercise price of $3.41 per share. These options expire on August 3, 2036 and vest one-third on August 3, 2027, with the balance vesting in equal quarterly installments over the next two years.
How do the RSUs granted to the RCKT COO vest over time?
The 73,313 RSUs granted to Stevens vest one-third on August 3, 2027. The remaining two-thirds vest in equal quarterly installments over the following two years, provided he continues employment with Rocket Pharmaceuticals during the vesting period.
How do the newly granted RCKT stock options vest for Christopher James Stevens?
The option to purchase 101,428 shares vests one-third on August 3, 2027. The remaining shares vest in equal quarterly installments over the subsequent two years, contingent on Stevens’ continued employment with Rocket Pharmaceuticals during that timeframe.
Were Stevens’ RCKT equity grants reported as made under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating these August 3, 2026 equity grants are not identified there as made pursuant to a Rule 10b5-1 trading plan. No separate footnote describes an applicable trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
